Analysis of a Phase 2b Study of GEN-003, a Genital Herpes Immunotherapy, Showed Significant Reductions in Viral Shedding and Lesion Rate Vs Placebo

BACKGROUND: GEN-003 is an investigational genital herpes immunotherapy comprising gD2ΔTMR, an HSV-2 antigen that induces neutralizing antibody and T cell responses, ICP4.2, an HSV-2 T cell antigen selected through human T cell screens, and Matrix-M2™, a saponin-based adjuvant. This Phase 2b study wa...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Open Forum Infect Dis
Main Authors: Heineman, Thomas C, Bernstein, David, Wald, Anna, Van Wagoner, Nicholas, Leone, Peter, Mayer, Kenneth, Lucksinger, Gregg, Win, Sandra, Koltun, William, Desai, Nisha, Oliphant, Thomas, Natenshon, Andrew, McNeil, Lisa K, Flechtner, Jessica B, Hetherington, Seth
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2017
Assuntos:
Abstracts
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5631773/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx162.140
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares